{"analyses":[{"groupDescription":"Null hypothesis was no difference between treatment groups","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"<0.0001","statisticalComment":"Stratified by baseline IVRS ECOG performance status and geographic region","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.9","upperLimit":"8.4","value":"8.0"},{"groupId":"OG001","lowerLimit":"7.1","upperLimit":"7.7","value":"7.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"232"}],"units":"Participants"}],"description":"Kaplan-Meier estimates of median time from randomization to either death or first observed disease progression, whichever occurred first. Participants were evaluated for tumor response according to modified Response Evaluation Criteria in Solid Tumors (RECIST) based on the response assessment from a blinded review of radiographic scans by the Independent Review Committee. Progressive disease defined as least a 20% increase in the sum of the longest diameters (SLD) of target lesions, taking as reference the nadir SLD recorded since the treatment started or the appearance of one or more new lesions, or the unequivocal progression of existing non-target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Panitumumab plus best supportive care (BSC). Panitumumab was administered by intravenous infusion at a dose of 6 mg/kg once every 2 weeks until participants developed progressive disease or were unable to tolerate study drug.","id":"OG000","title":"Panitumumab Plus BSC"},{"description":"Best supportive care defined as the best care available as judged appropriate by the investigator and according to institutional guidelines, including antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any symptomatic therapy as clinically indicated. For the purpose of this study, best supportive care does not include anti-neoplastic chemotherapy.","id":"OG001","title":"BSC Alone"}],"paramType":"MEDIAN","populationDescription":"Intention-to-treat (ITT)","reportingStatus":"POSTED","timeFrame":"From randomization to the data cut-off date of 30 June 2005. The median follow-up time was 20.0 weeks in the panitumumab plus BSC group and 18.2 weeks in the BSC alone group.","title":"Progression-free Survival Time","type":"PRIMARY","unitOfMeasure":"weeks"}